Jazz Pharmaceuticals plc
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Jazz Pharmaceuticals plc's yearly results (2022–2025), compared with companies in Ireland. Tap ? on any ratio for what it means.
What stands out
- Profit Cash Ratio: Over the last 3 years, every $100 of reported profit came with $621 of operating cash. Higher than 96% of companies in Ireland.
- Debt Due Cover Ratio: Debt due within a year is covered 1.3 times by its yearly operating cash. Lower than 91% of companies in Ireland.
- Growth Efficiency Ratio: Sales grew 17% in 3 years, but profit fell: $22 less profit per $100 of extra sales. Lower than 89% of companies in Ireland.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
$621Over the last 3 years, every $100 of reported profit came with $621 of operating cash.
Higher than 96% of companies in Ireland.
Self-Funding Ratio
12.8×Over the last 3 years its own operating cash covered its investment spending (capex) 12.8 times.
Higher than 84% of companies in Ireland.
Cash Locked Ratio
$25For every $100 of sales, $25 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $35 tied up three years earlier.
More money tied up than 81% of companies in Ireland.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 59% of companies in Ireland.
Growth Efficiency Ratio
−$22Sales grew 17% in 3 years, but profit fell: $22 less profit per $100 of extra sales.
Lower than 89% of companies in Ireland.
Asset Productivity Ratio
+17% / +8%In 3 years sales changed by +17% while total assets changed by +8%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
1.3×Debt due within a year is covered 1.3 times by its yearly operating cash.
Lower than 91% of companies in Ireland.
Cash Cushion Ratio
−21%Debt, after subtracting cash, equals 21% of its market value (net debt).
Lower than 61% of companies in Ireland.
Tangible Assets Ratio
46%Of every $100 the company owns, $46 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 85% of companies in Ireland.
Tangible Net Worth Ratio
NegativeGoodwill and other intangibles are larger than its whole net worth, so its tangible net worth is negative.
Less tangible than 74% of companies in Ireland.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Jazz Pharmaceuticals plc owes $0.57 for every $1 it owns. Jazz Pharmaceuticals plc made a loss in the year to Dec 2025, after a profit the year before.
Compared with companies in Ireland · latest annual results Dec 2025.
P/E ratio
14.7Investors pay $14.7 for every $1 of Jazz Pharmaceuticals plc's yearly profit, lower than 91% of companies in Ireland.
P/B ratio
2.90The share price is 2.90 times Jazz Pharmaceuticals plc's book value per share, lower than 56% of companies in Ireland.
Market cap
$13.9 BThe total market value of all of Jazz Pharmaceuticals plc's shares at today's price (share price × number of shares), smaller than 74% of companies in Ireland. PosiCap size class: Tito Cap.
Net worth (book value)
$4.8 BWhat Jazz Pharmaceuticals plc would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$73.97Net worth divided by the number of shares. The share price of $214.65 is 2.9 times this, which is the P/B above.
Return on equity (ROE)
22.1%Jazz Pharmaceuticals plc earned 22.1% on its shareholders' money over the last year, higher than 56% of companies in Ireland.
Owes vs Owns
0.57×Jazz Pharmaceuticals plc owes $0.57 for every $1 it owns (moderate), lower than 68% of companies in Ireland.
Dividend yield
NoneJazz Pharmaceuticals plc does not currently pay a dividend.
Revenue growth
+5%Revenue rose 5% in the year to Dec 2025, and grew 5% a year on average over 3 years.
Profit growth
LossJazz Pharmaceuticals plc made a loss in the year to Dec 2025, after a profit the year before.
Profit margin
-8.3%Jazz Pharmaceuticals plc lost $8 for every $100 of revenue.
Interest cover
2.7×Jazz Pharmaceuticals plc's operating profit covered its interest costs 2.7 times in the year to Dec 2025.
Cash vs debt
Net debtJazz Pharmaceuticals plc had $3.0 B more debt than cash (net debt) at Dec 2025.
Questions
What is Jazz Pharmaceuticals plc's P/E ratio?
Investors pay $14.7 for every $1 of Jazz Pharmaceuticals plc's yearly profit, lower than 91% of companies in Ireland.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Jazz Pharmaceuticals plc: $13.9 B ÷ $4.8 B (30 Jun 2026) = 2.9.
What is Jazz Pharmaceuticals plc's return on equity?
Jazz Pharmaceuticals plc earned 22.1% on its shareholders' money over the last year, higher than 56% of companies in Ireland.
How much does Jazz Pharmaceuticals plc owe compared with what it owns?
Jazz Pharmaceuticals plc owes $0.57 for every $1 it owns (moderate), lower than 68% of companies in Ireland.
Does Jazz Pharmaceuticals plc pay a dividend?
No. Jazz Pharmaceuticals plc does not currently pay a dividend.
Is Jazz Pharmaceuticals plc's revenue growing?
Revenue rose 5% in the year to Dec 2025, and grew 5% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.